With a humble start in 1989, with merely 50 employees, United Pharmaceuticals ventured into the pharmaceutical business with its target set on becoming a global healthcare company that is aware of social responsibilities of business with an inherent humanitarian concern for healthcare needs. Today United Pharmaceuticals operates in a facility of 15,500 sq meters and has more than 300 employees. Production has also diversified into different dosage forms with no compromise on reliability and quality. In a short span of time, United Pharmaceuticals has established a very strong and solid presence in the local market, the Middle East, and the European countries, with 90% of the sales occurring from exports, after being the first company in the Middle East to obtain European-GMP certificate. In 2002, and as part of its strategic expansion plans, United has acquired Stowic Resources, which is a United Kingdom based company with technologies for producing transdermal patches. In 2004, United has received the Brazilian GMP certificate (ANVISA) for its oral solid production lines. As part of its diversification and expansion strategies, United Pharmaceuticals has instituted relationships with two special sister companies; Tabuk Pharmaceutical Manufacturing Company in Saudi Arabia, which has a remarkably rich line of injectables, and with Jordan Chemical Laboratory (JCL), based in Palestine- that has a broad range of generic products with various pharmaceutical dosage forms. United Pharmaceuticals believe that long term planning is a key to milestone successes and therefore the company has planned the lucrative investment in different stages of the manufacturing process at the Fabro Group in Iran, and the Global Leverage Company in Libya. Correspondingly its project of establishing its armlength factory in North West Africa for the oral and injectable dosage forms is realized by the company's notable investment in Al-Kindi Company in Algeria.

To view this information, you must subscribe to PL Intelligence.

To view this information, you must subscribe to PL Intelligence.

To view this information, you must subscribe to PL Intelligence.

To view this information, you must subscribe to PL Intelligence.